Descriptive Epidemiology and Outcomes of Nonventilated Hospital-Acquired, Ventilated Hospital-Acquired, and Ventilator-Associated Bacterial Pneumonia in the United States, 2012-2019.

"Dr. Zilberberg’s institution received funding from Merck Sharpe & Dohme, Spero Therapeutics, Lungpacer Medical, Tetraphase, Nabriva, and Melinta; she disclosed that she has stock in J&J. Dr. Nathanson’s institution received funding from EviMed, LLC; he disclosed his company, OptiStatim, LLC, and has had a consulting agreement with Spero Therapeutics. Dr. Puzniak disclosed work for hire and that she is an employee and stockholder of Merck & Co. Drs. Puzniak and Shorr received funding from Merck & Co."

"Supported, in part, by a grant from Merck Sharp & Dohme, a subsidiary of Merck, Kenilworth, NJ. Dr. Zilberberg’s institution received funding from Merck Sharpe & Dohme, Spero Therapeutics, Lungpacer Medical, Tetraphase, Nabriva, and Melinta; she disclosed that she has stock in J&J. Dr. Nathanson’s institution received funding from EviMed, LLC; he disclosed his company, OptiStatim, LLC, and has had a consulting agreement with Spero Therapeutics. Dr. Puzniak disclosed work for hire and that she is an employee and stockholder of Merck & Co. Drs. Puzniak and Shorr received funding from Merck & Co."